நீரிழிவு வழக்கு அறிக்கைகள்

சுருக்கம்

Neonatal Diabetes-From Insulin to Oral Hypoglycemic Agent: Case Report

Sridevi A Naaraayan, Poovazhagi Varadharajan, Raghavan V Dhakshayani, and Rema Chandramohan

Neonatal diabetes mellitus (NDM) is a monogenic form of diabetes that occurs in first 6 months of life with an incidence of 1 in 100,000 to 500,000 live births [1]. It is one of the disorders in which the role of genetic analysis is not limited to confirmation of the diagnosis, but also required for selecting the appropriate therapy. Patients with certain mutations like the ones involving KCNJ11 and ABCC8 genes respond to oral sulfonylurea [2]. Successful switch over from subcutaneous insulin to oral sulfonylurea has been previously reported by various authors [3,4]. In this case report, we present our experience on transferring three patients with genetic mutations from insulin to oral glibenclamide in last three years.